The Pediatric infectious disease journal
Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5.
Ester Parada-Ricart, Núria Lledó-Gras, David Aragonès-Zabalza, Carmen Paima-Miguel, Ana Aparisi-Esteve, Marina Rodriguez-Hidalgo, Gabriel Zarauza-Pellejero, Xavier Viñas-Fernández, Maria Del Mar Albújar-Font
Published: 202510.1097/INF.0000000000005059
Abstract
BACKGROUND: Nirsevimab was incorporated into the universal infant immunization schedule in October 2023. While its effectiveness during the first season has been described, real-world data on the second season and its impact on other respiratory viru…
Preview only. Read the full abstract at the source